Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer
Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival of 54%
Strong efficacy signal observed in non-squamous NSCLC patients previously treated with the PD-1 inhibitor pembrolizumab, with median OS of 26.7 months and 91% ORR, including two complete responses
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of results from the CANFOUR trial with nadunolimab in combination with chemotherapy in the peer reviewed journal Lung Cancer. 40 patients with advanced NSCLC were treated with nadunolimab in combination with cisplatin/gemcitabine or carboplatin/pemetrexed for 4-6 cycles before continuing with nadunolimab as monotherapy or together with only gemcitabine or pemetrexed. The trial showed a manageable safety profile and encouraging median survival times, especially in patients with prior treatment with checkpoint inhibitors.
"These positive data published in Lung Cancer describe an important potential opportunity for nadunolimab, with possibilities to address a major unmet medical need" said Damian Marron, interim CEO of Cantargia. "We are particularly encouraged by the strong signal in the non-squamous NSCLC patients post PD-1 inhibitor treatment".
Lung cancer is one of the most common malignances worldwide and a leading cause of cancer-related deaths, with 84% of cases of the non-small cell lung cancer (NSCLC) type [1]. Immune checkpoint inhibitors targeting programmed death (ligand) 1 (PD-1/PD-L1) form part of the standard of care alongside chemotherapy for patients with advanced/metastatic NSCLC [2]. Treatment of NSCLC with immune checkpoint inhibitors can markedly improve tumor response rates and prolong survival, but not all patients respond to treatment and the development of treatment resistance is frequent [3, 4].
The CANFOUR Phase 2a trial with 40 advanced/metastatic NSCLC patients investigated nadunolimab in combination with cisplatin/gemcitabine (NCG) or carboplatin/pemetrexed (NCP) in first-line (1L), or in second-line (2L) after relapsing on pembrolizumab. Nadunolimab at doses of 1, 2.5 or 5 mg/kg were combined with chemotherapy for 4-6 cycles, followed by nadunolimab monotherapy or together with only gemcitabine or pemetrexed. Promising efficacy was reported with an OS of 13.7 months, which is observed to be better than historical references from randomized clinical trials of cisplatin/gemcitabine or platinum/pemetrexed in advanced NSCLC (median OS 10.3 and 11.3 months) [5,6].
Interestingly, highest efficacy was seen in patients previously treated with pembrolizumab (n=17) as compared to treatment naïve patients (n=23) (ORR 71% vs 44%; OS 15.7 vs 11.5 months). The 2L post-pembrolizumab patients had a markedly different tumor microenvironment at baseline with higher number of IL1RAP-positive immune cells, CD163+ macrophages, CD56+ NK cells and CD8+ T cells. Best response was seen in 2L non-squamous patients (n=11) which showed an outstanding ORR of 91%, PFS of 10.4 months and OS of 26.7 months, including two complete responders.
20 patients continued with nadunolimab monotherapy after having discontinued chemotherapy. One patient attained a complete response during monotherapy treatment, indicating a continued clinical effect of nadunolimab after completion of chemotherapy.
The combination showed a manageable safety profile with neutropenia being the most frequent reported adverse event.
The results support further investigation of the potential benefit in patients with non-squamous histology who previously progressed on immune checkpoint inhibitors, and to assess the potential benefit of continued nadunolimab monotherapy.
The publication, titled "Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet", by Paulus et al, is available online at the Lung Cancer | Journal | ScienceDirect.com by Elsevier and will be published Cantargia's web page.
References[1] Kratze et al. Cancer 2024 130(8) 1330-1348[2] Owen et al JCO Oncol Pract 2024 20(7) 893-898[3] Bagshi et al Ann Rev Path 2021 16 223-249[4] Jenkins et al Br J Cancer 2018 118(1) 9-16[5] Scagliotti et al J Clin Onc 2008 26(21) 3543-3551[6] Gandhi et al N Engl J Med 2018 378(22) 2078-2092
For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: damian.marron@cantargia.com
About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
About nadunolimab (CAN04)The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and the development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316, evaluates nadunolimab in combination with standard chemotherapies in patients with pancreatic ductal adenocarcinoma (PDAC) (gemcitabine/nab-paclitaxel) or non-small cell lung cancer (NSCLC) (platinum-based chemotherapies). Positive data show durable responses for combination therapy in 73 PDAC patients, resulting in a median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 40 NSCLC patients with median PFS of 7.2 months and a response rate of 55%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase 1b/2 trial TRIFOUR, NCT05181462, also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine.
AttachmentsCantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer
SOURCE: Cantargia
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Motor 1
4 minutes ago
- Motor 1
Another Automaker Shoots Down Apple CarPlay Ultra
Automakers are beginning to realize the value screens have to offer to their bottom lines. Digitizing the automotive experience, putting features behind paywalls, and nickel-and-diming customers to access amenities they could own outright just a few years ago make who controls the screen vital to securing those future profits. General Motors ditched Apple CarPlay for its proprietary system, and now automakers are pushing back on CarPlay Ultra , Apple's latest bid to control more of the in-car experience. BMW is one such brand. The German automaker confirmed with BMW Blog that it 'currently has no plans' to offer CarPlay Ultra in its vehicles. It's heavily invested in its own infotainment system called iDrive , which controls a range of vehicle functions due to its deep integration. Photo by: Aston Martin BMW joins Audi , Mercedes-Benz , Polestar , and Volvo among automakers that have no plans to offer the technology, despite Apple initially saying that they would. It's been three years since Apple first teased the upgraded version of CarPlay, initially listing several participating brands, but the industry continues to evolve. Some brands, including Porsche , Kia , Hyundai , and Genesis are still committed. Aston Martin was the first to launch Ultra in its vehicles. In a brief test, we thought it made the experience better . CarPlay Ultra takes over the entire in-car experience to bring an Apple-like feel to the gauges, in-car controls, and far more than just music and text messages. Photo by: Aston Martin It's unclear when another brand will launch Ultra for their vehicles, as it appears there's little incentive for most automakers to give up so much control. The battle for your attention and your money is coming to your car's screens, and automakers are starting to fight for it. But if customers like the technology and use their purchasing power to make their demands known, automakers might have no choice but to offer it. And if they don't, there are always workarounds. Why? Mercedes Gives Customers the One Thing They've Always Wanted: Microsoft Teams Mazda Explains Why It Removed the CX-5's Buttons Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Gallery: Aston Martin's Apple CarPlay Ultra 14 Source: Aston Martin Source: BMW Blog Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
Yahoo
33 minutes ago
- Yahoo
Renault reports overall sales growth in H1 2025
Renault Group has reported a 1.3% increase in its overall sales for the first half (H1) of 2025 compared to 2024, with 1,169,773 vehicles sold globally. In Europe, despite a passenger car (PC) market downturn of 1.0%, the group's sales rose by 5.4%, reaching 708,106 registered vehicles, with Sandero and Clio being the 'top-selling' vehicles. Switch Auto Insurance and Save Today! Affordable Auto Insurance, Customized for You The Insurance Savings You Expect Great Rates and Award-Winning Service The Renault brand itself saw a 2.7% growth in global sales to 808,413 vehicles. Outside Europe, the Renault brand experienced a 16.3% growth, outpacing the market's 4.7% increase, attributed to the Renault International Game Plan 2027, with 36% of sales currently made outside Europe. In Latin America, sales rose by 24%, with significant increases in Brazil and Argentina. Renault is said to lead in Colombia with a 14.6% market share. Additionally, sales in Morocco and South Korea saw substantial increases, benefitting from the Kardian launch and the success of Grand Koleos, respectively. Despite a declining commercial vehicle market, Renault noted that it maintains the second place in the European light commercial vehicle (LCV)market. The Group's electrification strategy is also paying off, with electric vehicle sales up by 57% in Europe, driven by the Renault 5 E-Tech electric, and hybrid sales growing by more than 36%. In the C and higher segments, Renault's sales surged by 52%, especially with Austral, Espace, and Rafale models. However, the Dacia Brand's global sales slightly dipped by 0.7% due to the Duster now being sold under the Renault brand in Turkey. Dacia Sandero is claimed to be the 'best-selling' model in Europe. In H1 2025, Dacia Spring's sales increased by 62.5%, and Dacia Bigster has seen a strong performance since its launch. Dacia's sales in Europe rose by 1.1%, with a market share of 4.5%. The brand's electrification efforts resulted in 23.5% of its registrations being in electrified engines in H1, with hybrid vehicles signifying 17.2% of its sales. Alpine also continues its growth with an 85% increase in registrations. The A290 is also said to bolster the brand's sales with 3,699 global registrations. The company noted that, the brand will have around 200 Alpine Stores this year, with a new store launch in Ireland anticipated this summer. Looking ahead, in H2, Renault said that it will continue its electric offensive in Europe with new launches, including the €25,000 version of Renault 5 E-Tech. The group announced that this year, it will launch seven vehicles, including the electric Renault 4 E-Tech, Dacia Bigster, and Boreal for the international market. Also included are two facelifts of Renault Austral and Renault Espace. Recently, Renault Group's board of directors announced the appointment of Duncan Minto as the interim CEO of Renault SA. "Renault reports overall sales growth in H1 2025" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Liverpool signs Ekitiké from Frankfurt and takes offseason spending to $342 million
Liverpool signed France forward Hugo Ekitiké from Eintracht Frankfurt on Wednesday to continue the Premier League champion's offseason spending spree. Ekitiké is Liverpool's latest big-money signing after Florian Wirtz, Jeremie Frimpong and Milos Kerkez — taking its outlay to around $342 million. The 23-year-old Ekitiké has joined for a fee of 69 million pounds ($93.5 million) and signed a six-year contract, a person with knowledge of the deal told The Associated Press. The person, who spoke on the condition of anonymity because details have not been made public, said the fee could rise by a further 10 million pounds ($13.5 million). Liverpool manager Arne Slot has been busy strengthening a team that won its record-equaling 20th English league title last season — in particular in attack. Wirtz, signed from Bayer Leverkusen last month for a fee that could rise to a British record 116 million pounds ($156 million), is considered one of the brightest talents in Europe. And Etikité is another player who has shone in Germany after leaving Paris Saint-Germain last year. He scored 22 in 48 appearances in his one full season with Frankfurt, which has made a big profit on him after buying him for a reported $19 million last year. Ekitiké's move comes weeks after Liverpool forward Diogo Jota died in a car accident in Spain. There is uncertainty about the future of other Liverpool forwards Darwin Nunez and Luis Diaz, who have both been targeted by teams in Europe during the offseason. The Merseyside club has not retained a league title since winning three in a row between 1982 and '84, which was before the inception of the Premier League. It is likely to face challenges from Manchester City, Arsenal and Chelsea, who have all been active in the transfer market since the end of the season. Ekitiké is the latest big-money departure from Frankfurt after forward Omar Marmoush joined Man City for a reported $73 million in January. Marmoush was the team's top-scorer at the time, but Ekitiké responded with his best performances in a Frankfurt shirt to help the team finish third in the Bundesliga for Champions League qualification. ___ James Robson is at ___ AP soccer:
